Pfizer wins early Ibrance approval in breast cancer
The FDA on 3 February gave its approval to Pfizer to market Ibrance (palbociclib) as a treatment for metastatic breast cancer (MBC) – granting the nod more than two months ahead of schedule.
The FDA on 3 February gave its approval to Pfizer to market Ibrance (palbociclib) as a treatment for metastatic breast cancer (MBC) – granting the nod more than two months ahead of schedule.